Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, C. Allison Stewart et al.|Cancer Cell|2021Cited by 930
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D. Campbell, Esther Drill, Christina Yau et al.|Cell Reports|2018Cited by 366
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y. Nabet, David S. Shames, Habib Hamidi et al.|Cancer Cell|2024Cited by 154
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B. Saad, Jia Wu, Qasem Al-Tashi et al.|The Lancet Digital Health|2023Cited by 108
Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysisYajing Wu, Joe Y. Chang, Vivek Verma et al.|Cancer|2023Cited by 36